Volume 2, Issue 2 (4-2018)                   Multidiscip Cancer Investig 2018, 2(2): 20-28 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mansouri S, Esmaeili R, Kaviani A, Rezaei M, Abdoli N, Mokhtari-Hesari P, et al . The Interaction Between the Expression of Proliferative Biomarkers and Clinical Characteristics in Breast Cancer. Multidiscip Cancer Investig. 2018; 2 (2) :20-28
URL: http://mcijournal.com/article-1-186-en.html
Abstract:   (1039 Views)
Introduction: Proliferation of cancer cells and the potential of metastasis depend on the activity of different biomarkers such as proliferative ones. Proliferative biomarkers including ki-67, cyclin E1, cyclin D1, p27, and p21 were analyzed through immunohistochemistry (IHC) in previous studies.
Methods: The current study aimed at investigating the utilizing role of RT-PCR in studying proliferative biomarkers including Ki-67, Cyclin E1, Cyclin D1, P27, and P21 to figure out the association between proliferative biomarkers and clinical aspects in patients with early breast cancer. One hundred and twenty-three patients with primary breast cancer were entered in the current study. Patients’ clinicopathological characteristics were obtained and also expressions of the proliferative biomarkers were investigated through RT-PCR on both cancerous and normal adjacent breast tissue.
Results: It was observed that in contrast to Cyclin D and P27, expression of Ki-67, Cyclin E, and P21 were higher in tumor samples compared with normal adjacent tissue. In addition, Cyclin D was higher in ER/PR positive and HER2 negative tumors and it was also higher in greater tumor size. Similarly, Cyclin E expression was higher in greater tumor size. Furthermore, patients with higher expression of P27 experienced worse prognosis.
Conclusions: Studying the proliferative biomarkers via a quantitative and automated method in Iranian patients showed that proliferative biomarkers had correlations with clinical aspects. Further studies to analyze the clinical utility of proliferative biomarkers in greater populations are warranted.
Full-Text [PDF 355 kb]   (197 Downloads)    
Type of Study: Original/Research Article | Subject: basic and translational research
Received: 2018/01/17 | Accepted: 2018/03/20 | ePublished: 2018/04/1

Add your comments about this article : Your username or Email:
CAPTCHA code

Send email to the article author


© 2018 All Rights Reserved | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb